PMID- 17206947
OWN - NLM
STAT- MEDLINE
DCOM- 20070607
LR  - 20181201
IS  - 0269-2813 (Print)
IS  - 0269-2813 (Linking)
VI  - 24
IP  - 11-12
DP  - 2006 Dec
TI  - Oesophageal mucosal involvement in patients with systemic sclerosis receiving 
      proton pump inhibitor therapy.
PG  - 1593-601
AB  - AIM: To assess the prevalence of oesophagitis, Barrett's oesophagus (BE) and 
      other oesophageal mucosal abnormalities in patients with systemic sclerosis (SSc) 
      without prior selection on digestive clinical presentation. We also investigated 
      the association between oesophageal endoscopic and manometric data with clinical 
      manifestations of SSc. METHODS: Oesophageal endoscopy and manometry were 
      performed in 133 consecutive patients with SSc, receiving proton pump inhibitor 
      (PPI) therapy since SSc diagnosis. RESULTS: Endoscopy revealed oesophagitis in 43 
      patients (32.3%), BE in 9 patients (6.8%), candidiasis in 7 patients (5.3%) and 
      hyperplastic polyp arising in ectopic gastric mucosa in 1 patient. Patients with 
      severe oesophageal motor impairment further exhibited a higher prevalence of 
      interstitial lung disease (ILD) when compared with those without. CONCLUSION: Our 
      study underlines the high frequency of oesophageal mucosal abnormalities in 
      unselected SSc patients receiving long-term PPI therapy. A relationship between 
      oesophagitis/BE and severe manometric motor disturbances was established; these 
      patients may require a higher regimen of PPI. Finally, our series indicates a 
      correlation between severe oesophageal motor disturbances and evidence for ILD in 
      patients, suggesting that gastro-oesophageal reflux may be one of the 
      contributing factors of ILD in SSc; this subgroup of patients may require close 
      monitoring of lung parameters.
FAU - Marie, I
AU  - Marie I
AD  - Department of Internal Medicine, Rouen University Hospital, Rouen Cedex, France. 
      isabelle.marie@chu-rouen.fr
FAU - Ducrotte, P
AU  - Ducrotte P
FAU - Denis, P
AU  - Denis P
FAU - Hellot, M F
AU  - Hellot MF
FAU - Levesque, H
AU  - Levesque H
LA  - eng
PT  - Journal Article
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (Proton Pumps)
SB  - IM
CIN - Aliment Pharmacol Ther. 2007 Apr 1;25(7):857; author reply 858-9. PMID: 17373925
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Esophagitis/*chemically induced
MH  - Female
MH  - Gastric Mucosa/*metabolism
MH  - Gastroesophageal Reflux/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Proton Pump Inhibitors
MH  - Proton Pumps/adverse effects
MH  - Scleroderma, Systemic/*drug therapy
EDAT- 2007/01/09 09:00
MHDA- 2007/06/08 09:00
CRDT- 2007/01/09 09:00
PHST- 2007/01/09 09:00 [pubmed]
PHST- 2007/06/08 09:00 [medline]
PHST- 2007/01/09 09:00 [entrez]
AID - APT3180 [pii]
AID - 10.1111/j.1365-2036.2006.03180.x [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2006 Dec;24(11-12):1593-601. doi: 
      10.1111/j.1365-2036.2006.03180.x.